ArticleAnnals of surgical oncology2026
Preoperative Myasthenia Gravis and Five-Year Outcomes After Thymoma Resection: A Multicenter Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe prognostic association of preoperative myasthenia gravis (MG) with outcomes after thymoma resection remains uncertain.
methodsThis three-center cohort included 1,368 patients undergoing thymoma resection (2009-2025); MG status was fixed at surgery. We evaluated overall survival and, after R0 resection, documented recurrence with death as a competing event. Stabilized weights adjusted for center, age, sex, histology, Masaoka-Koga stage, tumor diameter, and surgery year. Alternative analyses addressed recorded-M0 disease, detailed balance, operative extent, and follow-up.
resultsMyasthenia gravis was present in 257 patients (18.8%). Adjusted 5-year overall survival was 87.3% with MG and 97.3% without MG, an all-cause mortality-risk difference of 10 percentage points (95% confidence interval [CI] 5.2-15.1). Among 1,254 R0 resections, adjusted recurrence was 10% with MG and 2% without MG (difference, 8.0 points; 95% CI 3.2-13.3). After excluding 65 recorded M1a cases, mortality and recurrence differences were 8.6 points (95% CI 3.8-14.1; 28 deaths) and 7.6 points (95% CI 2.7-13.1; 17 recurrences). Detailed-category weighting yielded differences of 10.4 and 8.2 points; surgical and follow-up analyses were directionally consistent.
conclusionsPreoperative MG was associated with higher adjusted 5-year all-cause mortality and documented recurrence after R0 resection. Similar directions after excluding recorded M1a disease suggest that known pleural dissemination was not the sole explanation. These prognostic associations do not establish causality, and the survival difference cannot be attributed specifically to thymoma progression.
Indexed as
Identifiers
42832146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.